Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

BAA – Multiplex Diagnostic Platforms for Infectious Diseases

by Global Biodefense Staff
May 5, 2014

The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting the advanced development of promising integrated clinical sample-to-answer multiplex diagnostic platforms for emerging and re-emerging infectious diseases.

Under the newly issued Broad Agency Announcement (BAA), NIAID is seeking responses from organizations developing multiplex platforms which may be a single operating unit capable of accepting a clinical sample, or be composed of a cartridge and cartridge-operating unit.

The objective of the initiative is to advance the development of an integrated clinical sample-to-answer multiplex diagnostic platform up to and/or through the Food and Drug Administration (FDA) clearance process.  Responses to the BAA must specifically address current diagnostic testing capabilities for Bacillus anthracis, Yersinia pestis, Francisella tularensis, and a minimum of two commonly diagnosed prevalent pathogens with similar early symptoms as the three required biothreat pathogens (fever, malaise, flu-like symptoms, etc.).

At the end of the performance period, it is expected that the integrated clinical sample-to-answer multiplex platform will:

  • Detect all specified pathogens directly from a blood sample without a blood culture step
  • Be designed for use in a primary healthcare setting or in low resource settings
  • Generate actionable diagnostic results within a maximum of two hours

In addition to the detection of pathogens from blood, multiplex diagnostic tests to detect medically important pathogens in other types of clinical samples may be proposed as appropriate for an offeror’s instrument, including saliva, sputum, urine, feces and/or other types of clinical samples. The capability to provide information regarding antimicrobial sensitivity or resistance of the pathogens is also strongly desired.

NIAID estimates that the average annual total cost (direct and indirect costs combined) for up to 3 contracts is six million dollars.

Further requirements are detailed under Solicitation Number: NIHAI2014009.

Tags: AnthraxAntimicrobialsBAAF. tularensisMultiplexNIAIDNIHPOC DiagnosticsY. pestis

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC